California firm takes cannabinoid research personally

by Invesbrain Tuesday, July 18, 2017
Print This Article

California firm looks to Israel for personalized cannabinoid approach

The news magazine ISRAEL21c reports a U.S. biopharma company is teaming up with an Israeli counterpart to forward the use of cannabinoids in the field of personalized medicine.

California-based CURE Pharmaceutical recently signed a memorandum of understanding with Therapix Biosciences of Tel Aviv. The “research collaboration” will be done in conjunction with the eight hospitals and medical centres of Israel’s Assuta Medical Centers.

Therapix’s lead compound THX-TS01 is currently in phase 2 clinical trials to treat Tourette’s syndrome. It hopes to begin a Phase 1 clinical trial for another compound, THX-ULD01, for the treatment of mild cognitive impairment.

Both compounds employ an “FDA-approved synthetic THC.”

Therapix is also developing new cannabinoid delivery technologies including nasal and sublingual (under the tongue) methods.

(READ MORE)

CMAJ commentary argues for two-stream cannabis system

Arguing ‘recreational cannabis and cannabinoid-based drugs (including medical cannabis) are not equivalent,’ the authors of a commentary in the Canadian Medical Association Journal say Canada should continue with a separate medical cannabis stream after legalization.

In a report by EurekAlert!, Elizabeth Cairns and Dr. Melanie Kelly of Dalhousie University’s Department of Pharmacology, write that “(without) a program that supports medical use, patients may lose access to treatments that the Federal Court of Canada has deemed appropriate, which fosters safe and appropriate use."

The Task Force on Cannabis Legalization and Regulation also recommended a two-streamed system.
According to the EurekAlert! report, “the authors suggest that a medical stream for cannabis and cannabinoids would reduce risk to patients, provide incentives for research into the therapeutic effects of cannabinoids, and provide educational resources for health care practitioners on the latest advances in cannabinoid research.”

(READ MORE)

U.S.-German-Israeli deal links cancer diagnostics with cannabinoids

MMJ Reporter writes an American cannabinoid firm with an R&D foothold in Israel is teaming up with a German “world pioneer in cancer diagnostics.”

Cannabics Pharmaceuticals Inc. recently agreed to become “the exclusive international provider unit” of SIMFO GmbH’s Circulating Tumour Cell (CTC) diagnostics to people suffering with cancer and being treated with CBDs.

SIMFO previously initiated preclinical trials into CBDs and drug development with Cannabics’ cannabinoid formulations.

Cannabics’ R&D facility is “concentrated” in Israel.

(READ MORE)

Data on CBD analogue to be presented at neuroscience meeting

Stockhouse reports Califonia-based NEMUS Bioscience is set to present research on its CBD analogue at the Annual Meeting of the Society of Neuroscience this November.

The data, compiled by NEMUS’ R&D partner the University of Mississippi “will show the superiority of the NEMUS proprietary analogue of CBD, NB2222, versus plant-derived CBD in ameliorating pain in a validated mouse (murine) model of chemotherapy-induced peripheral neuropathy using an opioid as an active comparator.”

The firm will also present data on the anti-addictive potential of NB2222.

"We have been able to demonstrate that NB2222 was able to deliver analgesia comparable to morphine, which has been implicated in the current global opioid abuse epidemic. The research team then moved to the next step using a validated animal model of addiction to opioids to assess the anti-abuse potential of NB2222 as a therapeutic. We look forward to presenting the data this fall," said Dr. Kenneth Sufka, research professor with the National Center for Natural Products Research at UM.

(READ MORE)

Organigram to invest $15 million in industry-leading infused chocolate innovation

MONCTON, NB, May 20, 2019 /CNW/ – Anticipating the legalization of adult-use cannabis edibles, and ready to demonstrate a leadership position in the edibles market, Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQX: OGRMF), a licensed producer of cannabis, is pleased to annou...

4th annual Fore20 Golf Tournament tees off Aug. 25, 2019

The 4th annual Fore20 Golf Tournament and Pop-Up Market is fast approaching on Aug. 25– so you better mark your calendars if you don’t want to miss out on what’s becoming one of BC’s biggest and best 420-friendly events. Presented by the Cannabis Growers of Canada, Fore2...

Aurora Cannabis and UFC Join Forces to Advance CBD Research, Education, and Product Development

EDMONTON, May 21, 2019 /CNW/ – Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabis worldwide, and UFC®, the world’s premier mixed martial arts organization, are excited to announce an exclusive, multi-year, multi-million dollar,...

Canopy Growth CEO Bruce Linton explains why he wanted Acreage Holdings

Canadian licensed cannabis producer Canopy Growth (Canopy Growth Stock Quote, Chart TSX:WEED, NYSE:CGC) turned heads last month when it agreed to buy US multi-state operator Acreage Holdings if and when marijuana gets the go-ahead at the federal level, a legislative and social c...

Agripharm cannabis production license from Health Canada

CREEMORE, ON /CNW/ – Agripharm Corp. is pleased to announce that it has secured an outdoor cultivation licence from Health Canada. Agripharm will be growing its first outdoor crop this season utilizing its exclusive Canadian licence for Green House Seed Co.’s award-winning c...

Chronic Cooking: Popping Caramel Corn

Nothing gets a party or movie popping like caramel corn! On the latest episode of Chronic Cooking, host Craig Ex aka The Expert of Expert Joints is giving this timeless treat a THC twist. Caramel corn is the perfect snack for when the munchies kick in, but this delicious recipe ...

Buds & Baby Boomers

Steve, 51, remembers well the first time he got high. “I was a freshman in high school and my friend Chovi from India found me on the handball court where I had been spray-painting images of Alfred E. Newman with a stencil I’d made,” says Steve. “Chovi must’ve been abo...

The Cannabis Industry Lobbies on Capitol Hill for Banking & Equity

Over the past nine years, the National Cannabis Industry Association lobby days have been a hallmark of the progress we’ve seen in the cannabis industry, as the swarm of industry members heading to Washington, D.C. has only grown each year. This year, from May 21 to 23, about ...

Cansortium is poised to become an “eminent global cannabis company”, says Paradigm

US cannabis play Cansortium (Cansortium Stock Quote, Chart CSE:TIUM.U) got a coverage launch on Friday from Paradigm Capital’s Rahul Sarugaser, who started out with a “Buy” rating, saying TIUM.U has some of the strongest fundamentals and highest potential for growth among ...

IndyCar Team Picks Up CBD Sponsorship Just In Time For Big Race

IndyCar fans may notice during the Indianapolis 500 that the racing scene is starting to embrace marijuana. No, it’s not like racing officials issued a statement or anything saying that it is now perfectly acceptable for drivers to get blasted out of their minds before mashing...